© David Gray

Martin Shkreli, the notorious pharmaceutical boss who gained rights to a $13.50 malaria medication and then promptly raised its price to $750, has become the new CEO of cancer-treatment developer KaloBios, after buying out the company at fire-sale prices.

KaloBios Pharmaceuticals, trading on the Nasdaq as KBIO, saw its stock price jump by over 400 percent on Thursday following the announcement that Shkreli had been elected Chairman of the Board and Chief Executive Officer of the company. Its shares rose again on Friday – this time by over 100 percent.

Just a week prior, KaloBios had made an altogether different announcement. The company, whose mission is to improve “the lives of patients with innovative therapies,” began liquidating its assets and terminating two drug projects.

However, on Monday, Shkreli and his co-investors launched a buyout of shares, picking up some as cheaply as $0.61 each and ending up with 70 percent of the company by Tuesday. The stock price reached $18.75 on Friday, CNN reported. With the help of other backers, Shkreli was able to pump $3 million of equity into KaloBios.

To read the full article, click the link below: